Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Targets |
IC50: 8.92 nM (AKR1C3)[1]
|
---|---|
ln Vitro |
Compound 24 (AKR1C3-IN-9) exhibits a mild anti-proliferative activity on three different breast cancer cell lines (MCA-MB-231, MCF-7), with a range of inhibition of 100 μM[1]. In combination with 10-50 μM DOX, AKR1C3-IN-9 (10 μM, 25 μM, 50 μM; 72 h) reduces MCF-7 cell proliferation synergistically [1]. By inhibiting the proliferation and clonal survival of the MCF-7/DOX cell line, AKR1C3-IN-9 (10 μM; 8 d) and 50 μM DOX work together to restore sensitivity to DOX [1].
|
References |
Molecular Formula |
C20H20N2O4
|
---|---|
Molecular Weight |
352.383805274963
|
Exact Mass |
352.142
|
CAS # |
2924824-43-9
|
PubChem CID |
166449413
|
Appearance |
White to off-white solid powder
|
LogP |
3.4
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
5
|
Rotatable Bond Count |
6
|
Heavy Atom Count |
26
|
Complexity |
461
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
JUPXIAWRJFYWOF-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C20H20N2O4/c1-13-16(14(2)26-22-13)12-25-18-10-6-4-8-15(18)20(23)21-17-9-5-7-11-19(17)24-3/h4-11H,12H2,1-3H3,(H,21,23)
|
Chemical Name |
2-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-N-(2-methoxyphenyl)benzamide
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 83.33 mg/mL (236.48 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8378 mL | 14.1892 mL | 28.3785 mL | |
5 mM | 0.5676 mL | 2.8378 mL | 5.6757 mL | |
10 mM | 0.2838 mL | 1.4189 mL | 2.8378 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.